SS Innovations International (NASDAQ: SSII) has announced the launch of Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo, utilizing the SSi Mantra 3.0 surgical robotic system. The program commenced with a robotic-assisted left internal mammary artery (LIMA) takedown performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. This development was highlighted in a recent company video, which noted that Kings Hospital has completed more than 25 robotic procedures in just three weeks.
The introduction of robotic cardiac surgery in Sri Lanka represents a significant advancement in the region's healthcare capabilities. Robotic-assisted cardiac procedures offer the potential for smaller incisions, reduced pain, and faster recovery times compared to traditional open-heart surgery. By bringing this technology to Sri Lanka, SS Innovations is not only expanding its global footprint but also enabling local surgeons to perform complex cardiac interventions with greater precision.
SS Innovations reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter. The company's second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528. These figures indicate rising utilization of the company's installed base, as more hospitals adopt and integrate the SSi Mantra system into their surgical practices.
The next major corporate milestone for SS Innovations is regulatory expansion. The company is pursuing U.S. Food and Drug Administration (FDA) clearance and European CE marking for the SSi Mantra system. Achieving these certifications would open doors to two of the largest healthcare markets in the world, potentially accelerating adoption and driving further revenue growth.
For leaders in business and technology, this announcement underscores the growing role of robotics and AI in healthcare. Surgical robotics is a rapidly evolving field, with companies like SS Innovations competing to deliver innovative solutions that improve patient outcomes and operational efficiency. The successful deployment of robotic cardiac surgery in Sri Lanka demonstrates the potential for these technologies to transcend borders and address unmet medical needs in emerging markets.
Investors and industry watchers should note SS Innovations' forward-looking statements, which are subject to risks and uncertainties. As with any medical device company, regulatory approvals and market acceptance are critical factors that could impact future performance. The company's progress in Sri Lanka, however, provides a positive signal about the demand for its technology and its ability to execute on international expansion.
The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. For full terms of use and disclaimers, please see https://IBN.ai/Disclaimer.
